Recent discussions on X about Prime Medicine (PRME) have centered around the company’s latest public stock offering of 38 million shares priced at $3.30 each, raising $125 million. Many users have noted the significant drop in stock price following the announcement, with some expressing concern over the dilution impact on existing shareholders. However, there’s also a sense of relief among some who believe this addresses a critical need for capital, potentially easing short-term financial pressures.
Additionally, posts on X have highlighted encouraging early clinical data from Prime Medicine’s programs, particularly in chronic granulomatous disease (CGD), with some users pointing to promising patient outcomes as a reason for long-term optimism. Discussions also touch on the company’s innovative technology and potential regulatory advancements, with a few voices suggesting that the current stock price might not reflect the firm’s future potential. The conversation remains dynamic as investors weigh both the immediate financial challenges and the broader therapeutic promise.
Note: This discussion summary was generated from an AI condensation of post data.
Prime Medicine Insider Trading Activity
Prime Medicine insiders have traded $PRME stock on the open market 10 times in the past 6 months. Of those trades, 10 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PRME stock by insiders over the last 6 months:
- ROBERT NELSEN purchased 3,030,300 shares for an estimated $9,999,990
- VENTURE PARTNERS X, LLC ARCH purchased 3,030,300 shares for an estimated $9,999,990
- VENTURE PARTNERS XII, LLC ARCH purchased 3,030,300 shares for an estimated $9,999,990
- DAVID R. LIU has made 4 purchases buying 84,000 shares for an estimated $163,016 and 0 sales.
- ALLAN REINE (Chief Executive Officer) purchased 125,000 shares for an estimated $147,150
- ANN L. LEE (Chief Technical Officer) purchased 100,000 shares for an estimated $112,999
- RICHARD BRUDNICK (Chief Business Officer) purchased 20,000 shares for an estimated $23,790
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Prime Medicine Hedge Fund Activity
We have seen 53 institutional investors add shares of Prime Medicine stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUMITOMO MITSUI TRUST GROUP, INC. removed 1,331,505 shares (-45.5%) from their portfolio in Q2 2025, for an estimated $3,288,817
- WESTWOOD HOLDINGS GROUP INC removed 883,129 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,757,426
- ARK INVESTMENT MANAGEMENT LLC removed 772,503 shares (-25.0%) from their portfolio in Q2 2025, for an estimated $1,908,082
- RENAISSANCE TECHNOLOGIES LLC added 447,600 shares (+inf%) to their portfolio in Q1 2025, for an estimated $890,724
- WALLEYE CAPITAL LLC removed 403,739 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $803,440
- BANK OF AMERICA CORP /DE/ removed 317,687 shares (-73.8%) from their portfolio in Q1 2025, for an estimated $632,197
- AQR CAPITAL MANAGEMENT LLC added 227,749 shares (+1419.4%) to their portfolio in Q1 2025, for an estimated $453,220
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Prime Medicine Analyst Ratings
Wall Street analysts have issued reports on $PRME in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Market Outperform" rating on 05/20/2025
- Chardan Capital issued a "Buy" rating on 05/19/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 03/04/2025
To track analyst ratings and price targets for Prime Medicine, check out Quiver Quantitative's $PRME forecast page.
Prime Medicine Price Targets
Multiple analysts have issued price targets for $PRME recently. We have seen 5 analysts offer price targets for $PRME in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Samantha Semenkow from Citigroup set a target price of $1.5 on 05/27/2025
- Silvan Tuerkcan from JMP Securities set a target price of $6.0 on 05/20/2025
- Geulah Livshits from Chardan Capital set a target price of $12.0 on 05/19/2025
- Arthur He from HC Wainwright & Co. set a target price of $10.0 on 03/19/2025
- Silvan Tuerkcan from Citizens Capital Markets set a target price of $10.0 on 03/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
